Sri Lanka VAT and SSCL in the Fee Structure
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The tax structure of Sri Lanka’s device regulatory fees works as follows: the US-dollar-denominated fee is first converted into rupees at the central bank’s selling rate of the last working day of the previous month, and then 18% VAT and 2.5% SSCL (Social Security Contribution Levy) are added on top; stamp duty is shown as “—” (not charged) in the monthly fee schedule. Taking the foreign new application of 1,000 US dollars as the example: converted it is 319,312 rupees, VAT adds 58,913.06 rupees, SSCL adds 7,982.80 rupees, and the total is 386,207.86 rupees. The two levies together add 20.5% to every converted figure, so the tax layer is not a rounding detail but a structural component of any Sri Lankan fee budget.
- Fees are denominated in US dollars and converted at the CBSL selling rate of the last working day of the previous month.
- VAT is charged at 18% on top of the converted amount.
- SSCL is charged at 2.5% on top of the converted amount.
- Stamp duty is listed as — in the monthly fee schedule for the period shown.
- Example from the April 2026 schedule: 1,000 USD → 319,312 rupees; VAT 58,913.06; SSCL 7,982.80; total 386,207.86 rupees.
- Actual outlay is approximately the dollar amount multiplied by the rate and by 1.205.
2. Legal basis
The structure is published in the NMRA medical device monthly fee schedules, which state the currency, the conversion basis, and the levies applied. The table below reproduces the elements of the structure together with the worked example from the April 2026 schedule.
| Item | Rate / amount | Source |
| Pricing basis | Fees are denominated in US dollars | NMRA medical device monthly fee schedule |
| Conversion rate | The CBSL selling rate published on the last working day of the previous month | Same source |
| VAT | 18% | Same source |
| SSCL | 2.5% | Same source |
| Stamp duty | Listed as — | Same source |
| Example (April 2026 schedule) | 1,000 USD → 319,312 Rs.; VAT 58,913.06; SSCL 7,982.80; total 386,207.86 Rs. | Same source |
The order of operations matters for verification: the dollar amount is fixed, the rate is fixed by the month, and only then are the two percentage levies applied to the converted figure. Recomputing a total in that order — dollar, rate, VAT, SSCL, sum — allows any figure on a payment request to be checked independently against the schedule from which it was drawn. The worked example from the April 2026 schedule shows the full chain in one line — 1,000 US dollars at 319.312 rupees per dollar, plus VAT of 58,913.06 rupees and SSCL of 7,982.80 rupees, reaching 386,207.86 rupees — and reproducing that chain once per new fee item is the most reliable habit for keeping payment documents error-free.
3. Expert insights
Insight one: the actual outlay is approximately the dollar amount × the exchange rate × 1.205. The 18% VAT and the 2.5% SSCL together represent 20.5% of additional burden. Budgeting on the nominal dollar amount alone will understate the cost by about a fifth. The multiplier is stable across fee items because both levies are percentages, so once it is understood, the quick mental check of any quoted rupee total becomes straightforward: divide by the rate, and the implied dollar base should be roughly 83% of the rupee figure.
Insight two: the exchange rate changes monthly, so the rupee amount changes monthly. The fee schedule is published monthly, and any citation must carry the month and the conversion rate. This is the largest difference between this market and Pakistan (fixed rupee amounts) or Singapore (fixed Singapore-dollar amounts). In those markets a fee figure quoted last year remains quotable today; in Sri Lanka the same dollar fee produces a different rupee total every month, so comparative tables across markets must keep the dollar figures as the common denominator and treat the rupee columns as month-stamped snapshots.
Insight three: a stamp duty column shown as “—” does not mean it will never be charged. What the table lists is the position for the current period, and whether stamp duty applies is determined by the official fee schedule in force. The correct practice is to leave the line present in every budget with its current value, so that if a later schedule introduces a figure there, the change is caught by routine schedule review rather than by a payment discrepancy.
4. Practical recommendations
- GRZAN uses a uniform dual-currency annotation method in quotations: the main amount is written in US dollars (stable and comparable), with the converted rupee total for the current period in brackets (usable directly for payment requests), and a note stating the official fee schedule of the applicable year and month and the official conversion rate of that period.
- This method serves two audiences at once: group-level comparisons of costs across countries stay on the dollar basis, while the local team executes payment on the rupee figure without re-deriving it.
- Verify every total by recomputing in order: dollar amount, month’s rate, 18% VAT, 2.5% SSCL, sum.
- Record the CBSL dollar selling rate applied, so each payment request carries its own conversion evidence.
- Check the stamp duty line of the current schedule each month rather than assuming it remains uncharged.
- Archive the monthly schedule used for each quotation, so any later question about a historical figure can be answered from the source document.
5. Verification checklist
- □ The version and validity period of the current monthly fee schedule have been confirmed
- □ The current CBSL dollar selling rate has been recorded
- □ VAT has been calculated at 18%
- □ SSCL has been calculated at 2.5%
- □ The stamp duty column treatment has been checked
- □ The applicable month and conversion rate have been stated on the quotation
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Regulatory information verified as of 28 October 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us